Holen Sie sich die Stockscreener-App
24.45
1.83%
0.44
Vorhandelsmarkt:
14.80
-9.65
-39.47%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Stock Tumbles 40%. Why the Biotech’s Shares Are Sinking. - Barron's
Palantir, Sarepta, Amazon, AMD, Pfizer, and More Stock Market Movers - Barron's
Sarepta Therapeutics (SRPT) Stock Crashes as Nine-Year Trial Ends in Disappointment - CoinCentral
Biggest stock movers Tuesday: PLTR, SRPT, and more (NASDAQ:PLTR) - Seeking Alpha
Sarepta slumps as gene therapy setback adds to drug pipeline woes - Reuters
Pinnacle Associates Ltd. Has $997,000 Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - Stocktwits
Sarepta Therapeutics (SRPT) to Join S&P SmallCap 600 - GuruFocus
Why Sarepta Therapeutics Shares Tumbled Today - TipRanks
Why Is Sarepta Stock (SRPT) Crashing in Pre-Market Today? - TipRanks
Earnings Snapshot: Sarepta Q3 beat; ESSENCE study did not meet statistical significance on primary endpoint - MSN
Sarepta Therapeutics Inc (SRPT) Q3 2025 Earnings Call Highlights: Resilient Revenue Amidst ... - Yahoo Finance
Sarepta Therapeutics Stock Crashes After-Hours On DMD Trial Failure, Q3 Print — Retail Still Sees Long-Term Comeback - Stocktwits
Sarepta Therapeutics Reports Q3 2025 Financial Results - TipRanks
Transcript : Sarepta Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE - BioSpace
Sarepta Therapeutics (SRPT): Assessing Valuation After Q3 Earnings Reveal Swing to Net Loss - simplywall.st
Sarepta's shares sink after antisense DMD therapies fail confirmatory trial - FirstWord Pharma
Sarepta Therapeutics: Q3 Earnings Snapshot - CTPost
Sarepta Therapeutics Outpaces Forecasts On Gene Therapy Strength - Finimize
Earnings call transcript: Sarepta Therapeutics beats Q3 2025 EPS forecast - Investing.com
Sarepta's shares plunge after trial for muscle-wasting disease drugs miss key goal - Reuters
Sarepta Therapeutics Stock: Strong Q3 and ESSENCE Study Results Propel Future Growth Plans - parameter.io
Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success - MarketWatch
Sarepta Therapeutics (SRPT) Shares Plunge 20% After Trial Setbac - GuruFocus
Sarepta Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Sarepta Says Older Muscle Disease Drugs Failed Confirmatory Trial - Bloomberg.com
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
Sarepta Therapeutics (SRPT) Beats Q3 Earnings Expectations Despi - GuruFocus
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina - Investing.com Nigeria
Sarepta plunges after late-stage Duchenne trial failure - MSN
Sarepta plunges after late-stage Duchenne trial failure (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics Stock Is Tumbling After The Close: Here's Why - Benzinga
Sarepta reports mixed results from confirmatory trial for rare disease therapies - Investing.com
Sarepta Therapeutics tumbles after ESSENCE trial misses primary endpoint By Investing.com - Investing.com Nigeria
Sarepta Therapeutics tumbles after ESSENCE trial misses primary endpoint - Investing.com India
Sarepta Therapeutics Q3 2025 Earnings: Revenue Surpasses Estimat - GuruFocus
Sarepta shares dive as gene therapy misses late-stage main goal - TradingView
Sarepta Therapeutics Q3 revenue beats estimates on strong show from gene therapy ELEVIDYS - MarketScreener
Sarepta's Duchenne gene therapy misses main goal in late-stage study; shares fall - Yahoo! Finance Canada
Sarepta stock plunges after ESSENCE trial misses primary endpoint By Investing.com - Investing.com Canada
Sarepta's Duchenne gene therapy misses main goal in study - MarketScreener
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests - Investor's Business Daily
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q3 Adjusted Loss $0.13 per Share - MarketScreener
Sarepta completes confirmatory study for duchenne therapies, study misses primary endpoint - StreetInsider
Price-Driven Insight from (SRPT) for Rule-Based Strategy - news.stocktradersdaily.com
Is Sarepta Therapeutics Inc. stock supported by strong cash flows2025 Short Interest & Community Consensus Picks - newser.com
SRPT Crosses Above Average Analyst Target - Nasdaq
Forecasting Sarepta Therapeutics Inc. price range with options dataIPO Watch & Real-Time Chart Pattern Alerts - newser.com
What market sentiment indicators show for Sarepta Therapeutics Inc. (AB3A) stockQuarterly Performance Summary & Consistent Return Investment Signals - newser.com
Can Sarepta Therapeutics Inc. (AB3A) stock attract analyst upgrades2025 Support & Resistance & Weekly Momentum Picks - newser.com
Smart tools for monitoring Sarepta Therapeutics Inc.’s price action2025 Volume Leaders & Long-Term Capital Growth Ideas - newser.com
Will breakout in Sarepta Therapeutics Inc. lead to full recoveryGold Moves & Accurate Intraday Trade Tips - newser.com
Is Sarepta Therapeutics Inc. stock ready for a breakoutQuarterly Portfolio Review & Daily Profit Focused Screening - newser.com
Combining machine learning predictions for Sarepta Therapeutics Inc.July 2025 Trade Ideas & Stock Portfolio Risk Management - newser.com
State of New Jersey Common Pension Fund D Grows Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
How Sarepta Therapeutics Inc. stock benefits from global expansionMarket Risk Summary & Weekly High Potential Stock Alerts - newser.com
Relative strength of Sarepta Therapeutics Inc. in sector analysisQuarterly Profit Review & Community Verified Watchlist Alerts - newser.com
Will Sarepta Therapeutics Inc. stock benefit from sector rotation2025 AllTime Highs & Consistent Return Investment Signals - newser.com
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):